Dward P. Taibi Resigns from Board of Directors of SIGA Technologies, Inc
October 02, 2020 at 04:42 pm EDT
Share
On September 30, 2020, Edward P. Taibi resigned from the Board of Directors of SIGA Technologies, Inc., effective as of such date. Mr. Taibi did not resign as a result of any disagreement with the Company relating to the Company's operations, policies or practices.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
SIGA TECHNOLOGIES, INC. 